G. Smits

发表

Pharmacological characterization of AMP 579, a novel adenosine A1/A2 receptor agonist and cardioprotective

A. Spada, K. Clark, M. Jarvis, 1998 .

Regional hemodynamic dose-response of lemakalim and glybenclamide in anesthetized rats.

B. Cox, M. Perrone, G. Smits, 1997, Journal of cardiovascular pharmacology.

Reversal of Low Dose Angiotensin Hypertension by Angiotensin Receptor Antagonists

E. H. Blaine, J. P. Koepke, G. Smits, 1991, Hypertension.

Cardiovascular and antilipolytic effects of the adenosine agonist GR79236.

D. Colussi, B. Cox, M. Perrone, 1995, Pharmacology.

Effects of Adenosine Receptor Subtype A 1 on Ventricular and Renal Function

F. Spinale, R. Mukherjee, Jennifer Davis, 2001, Journal of cardiovascular pharmacology.

Thiorphan, an Inhibitor of Endopeptidase 24.11, Potentiates the Natriuretic Activity of Atrial Natriuretic Peptide

E. H. Blaine, A. Trapani, J. P. Koepke, 1989, Journal of cardiovascular pharmacology.

A(1) receptor blockade induces natriuresis with a favorable renal hemodynamic profile in SHHF/Mcc-fa(cp) rats chronically treated with salt and furosemide.

W. Herzer, E. Jackson, S. Tofovic, 2001, The Journal of pharmacology and experimental therapeutics.

Renal effects of BG9928, an A1 adenosine receptor antagonist, in rats and nonhuman primates

Xiaowei Jin, A. Gill, E. Whalley, 2003 .

Effect of endopeptidase 24.11 inhibition in conscious cardiomyopathic hamsters.

A. Trapani, G. Smits, D. E. Mcgraw, 1990, The Journal of pharmacology and experimental therapeutics.

Cardiorenal effects of adenosine subtype 1 (A1) receptor inhibition in an experimental model of heart failure.

F. Spinale, G. P. Escobar, F. A. Crawford, 2002, Journal of the American College of Surgeons.

Angiotensin subtype 1 blockade selectively potentiates adenosine subtype 2-mediated vasodilation.

B. Cox, M. Perrone, G. Smits, 1993, Hypertension.

Potent and orally bioavailable 8-bicyclo[2.2.2]octylxanthines as adenosine A1 receptor antagonists.

Xiaowei Jin, J. Linden, R. Petter, 2006, Journal of medicinal chemistry.

Nonpeptide angiotensin II antagonists: N-phenyl-1H-pyrrole derivatives are angiotensin II receptor antagonists.

E G McMahon, J. Collins, D. Reitz, 1993, Journal of medicinal chemistry.

Novel diamino derivatives of [1,2,4]triazolo[1,5-a][1,3,5]triazine as potent and selective adenosine A2a receptor antagonists.

T. Engber, Xiaowei Jin, R. Petter, 2004, Journal of medicinal chemistry.

Norbornyllactone-substituted xanthines as adenosine A(1) receptor antagonists.

Xiaowei Jin, J. Linden, R. Petter, 2006, Bioorganic & medicinal chemistry.

In vitro and in vivo characterization of an A1-selective adenosine agonist, RG14202.

D. Colussi, B. Cox, M. Perrone, 1993, The Journal of pharmacology and experimental therapeutics.

Interaction of ANP and bradykinin during endopeptidase 24.11 inhibition: renal effects.

A. Trapani, G. Smits, D. E. Mcgraw, 1990, The American journal of physiology.

Comparison of Three Different A1 Adenosine Receptor Antagonists on Infarct Size and Multiple Cycle Ischemic Preconditioning in Anesthetized Dogs

G. Gross, Xiaowei Jin, E. Whalley, 2004, Journal of Pharmacology and Experimental Therapeutics.

Cardioprotective effects of the novel adenosine A1/A2 receptor agonist AMP 579 in a porcine model of myocardial infarction.

M. McVey, K. Clark, B. Cox, 1998, The Journal of pharmacology and experimental therapeutics.

Regional hemodynamic effects of purinergic P2 receptor subtype agonists in rats.

B. Cox, G. Smits, 1996, The Journal of pharmacology and experimental therapeutics.

Dual A1/A2B Receptor Blockade Improves Cardiac and Renal Outcomes in a Rat Model of Heart Failure with Preserved Ejection Fraction

E. Jackson, A. Deykin, E. Whalley, 2016, The Journal of Pharmacology and Experimental Therapeutics.

Hemodynamic basis for the depressor activity of zaprinast, a selective cyclic GMP phosphodiesterase inhibitor.

E. H. Blaine, A. Trapani, G. Smits, 1991, The Journal of pharmacology and experimental therapeutics.

Pharmacology of SC‐52458, an Orally Active, Nonpeptide Angiotensin AT1 Receptor Antagonist

R. Schmidt, D. Reitz, V. Corpus, 1993, Journal of cardiovascular pharmacology.

Dual A1/A2B Receptor Blockade Improves Cardiac and Renal Outcomes in a Rat Model of Heart Failure with Preserved Ejection Fraction

E. Jackson, A. Deykin, E. Whalley, 2016, The Journal of Pharmacology and Experimental Therapeutics.

Synthesis and structure-activity relationships of nonpeptide, potent triazolone-based angiotensin II receptor antagonists.

D. Reitz, V. Corpus, J. P. Koepke, 1993, Journal of medicinal chemistry.

Piperazine derivatives of [1,2,4]triazolo[1,5-a][1,3,5]triazine as potent and selective adenosine A2a receptor antagonists.

T. Engber, Xiaowei Jin, R. Petter, 2004, Journal of medicinal chemistry.

Cardiovascular pharmacology of the adenosine A1/A2-receptor agonist AMP 579: coronary hemodynamic and cardioprotective effects in the canine myocardium.

M. McVey, K. Clark, B. Cox, 1999, Journal of cardiovascular pharmacology.